CA2898032C - Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains - Google Patents
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains Download PDFInfo
- Publication number
- CA2898032C CA2898032C CA2898032A CA2898032A CA2898032C CA 2898032 C CA2898032 C CA 2898032C CA 2898032 A CA2898032 A CA 2898032A CA 2898032 A CA2898032 A CA 2898032A CA 2898032 C CA2898032 C CA 2898032C
- Authority
- CA
- Canada
- Prior art keywords
- adjustment member
- mitigation
- specific binding
- binding domains
- adverse events
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002411 adverse Effects 0.000 title 1
- 230000000116 mitigating effect Effects 0.000 title 1
- 230000009870 specific binding Effects 0.000 title 1
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 238000007789 sealing Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762718P | 2013-02-08 | 2013-02-08 | |
| US61/762,718 | 2013-02-08 | ||
| US201361811526P | 2013-04-12 | 2013-04-12 | |
| US61/811,526 | 2013-04-12 | ||
| PCT/EP2014/052406 WO2014122251A2 (en) | 2013-02-08 | 2014-02-07 | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2898032A1 CA2898032A1 (en) | 2014-08-14 |
| CA2898032C true CA2898032C (en) | 2021-06-15 |
Family
ID=50231117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2898032A Active CA2898032C (en) | 2013-02-08 | 2014-02-07 | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9688760B2 (OSRAM) |
| EP (2) | EP2953630B1 (OSRAM) |
| JP (2) | JP6567425B2 (OSRAM) |
| AR (1) | AR094740A1 (OSRAM) |
| AU (2) | AU2014214020B2 (OSRAM) |
| CA (1) | CA2898032C (OSRAM) |
| ES (1) | ES2811764T3 (OSRAM) |
| JO (1) | JO3529B1 (OSRAM) |
| MX (2) | MX368842B (OSRAM) |
| TW (2) | TW201929865A (OSRAM) |
| UY (1) | UY35313A (OSRAM) |
| WO (1) | WO2014122251A2 (OSRAM) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2832360C (en) * | 2011-04-28 | 2022-05-03 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| US20130058936A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| US9486475B2 (en) * | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
| CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| PT2961771T (pt) | 2013-02-26 | 2020-02-28 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea |
| US10101247B2 (en) * | 2013-07-19 | 2018-10-16 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
| EP3736292B1 (en) | 2013-12-17 | 2024-05-08 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| LT3149480T (lt) | 2014-05-30 | 2019-04-25 | Amgen Research (Munich) Gmbh | B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas |
| CR20170032A (es) | 2014-08-04 | 2017-04-04 | Hoffmann La Roche | Moleculas biespecíficas de unión a antígeno activadoras de células t |
| EA201790569A1 (ru) | 2014-09-12 | 2017-08-31 | Дженентек, Инк. | Антитела и иммуноконъюгаты против cll-1 |
| MX2017006571A (es) | 2014-11-20 | 2017-09-29 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas activadoras de celulas t. |
| PL3221357T3 (pl) | 2014-11-20 | 2020-11-02 | F. Hoffmann-La Roche Ag | Wspólne łańcuchy lekkie i sposoby zastosowania |
| HRP20240959T1 (hr) | 2014-11-20 | 2024-10-25 | F. Hoffmann - La Roche Ag | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1 |
| CN107847568B (zh) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | 抗cll-1抗体和使用方法 |
| US10323094B2 (en) | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
| US11890301B2 (en) * | 2015-08-28 | 2024-02-06 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CN106554414B (zh) * | 2015-09-18 | 2019-04-23 | 上海科济制药有限公司 | 抗cd19全人抗体以及靶向cd19的免疫效应细胞 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| MA43025A (fr) | 2015-10-02 | 2021-05-26 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3 |
| US10101248B1 (en) * | 2015-12-02 | 2018-10-16 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
| EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
| AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
| MX2018011542A (es) | 2016-03-22 | 2019-02-07 | Hoffmann La Roche | Moleculas biespecificas de celulas t activadas por proteasas. |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| JP6225321B1 (ja) | 2016-08-31 | 2017-11-08 | 王子ホールディングス株式会社 | ポリ硫酸ペントサンの製造方法 |
| CN111148749A (zh) | 2016-08-31 | 2020-05-12 | 王子控股株式会社 | 酸性低聚木糖的生产方法和酸性低聚木糖 |
| PL3519437T3 (pl) | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste przeciwko p95HER2 |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| JP6281659B1 (ja) | 2017-02-28 | 2018-02-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン、医薬組成物及び抗凝固剤 |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| US11278485B2 (en) | 2017-05-31 | 2022-03-22 | Oji Holdings Corporation | Moisturizing topical preparation |
| SG11202002250VA (en) | 2017-09-12 | 2020-04-29 | Oji Holdings Corp | Pentosan polysulfate and method for producing pentosan polysulfate |
| JP7654240B2 (ja) | 2017-09-19 | 2025-04-01 | マサチューセッツ インスティテュート オブ テクノロジー | キメラ抗原受容体ｔ細胞治療のための組成物およびその使用 |
| EP3730521B1 (en) | 2017-12-20 | 2023-05-17 | Oji Holdings Corporation | Pentosan polysulfate and medicine containing pentosan polysulfate |
| CN120154716A (zh) | 2018-01-22 | 2025-06-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| JP7774961B2 (ja) | 2018-02-06 | 2025-11-25 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ |
| AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| SG11202100935TA (en) | 2018-09-28 | 2021-02-25 | Massachusetts Inst Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| WO2020221792A1 (en) * | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| US11845799B2 (en) | 2019-12-13 | 2023-12-19 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
| US11896619B2 (en) | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
| CA3173527A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
| US12268707B2 (en) * | 2020-03-12 | 2025-04-08 | Sydney David Cullis-Hill | Treatment for coronavirus infection and associated cytokine toxicity |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| US12433954B2 (en) | 2020-05-01 | 2025-10-07 | Massachusetts Institute Of Technology | Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| TW202519548A (zh) | 2020-06-19 | 2025-05-16 | 瑞士商赫孚孟拉羅股份公司 | 與 cd3 及 cd19 結合之抗體 |
| CA3194771A1 (en) * | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| EP4240766A2 (en) | 2020-11-04 | 2023-09-13 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
| JP7402381B2 (ja) | 2020-11-04 | 2023-12-20 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| CN112521513B (zh) * | 2020-12-15 | 2021-08-24 | 青岛西凯生物技术有限公司 | 一种靶向cd19的嵌合抗原受体(car)及其应用 |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| JP2023546368A (ja) | 2021-05-14 | 2023-11-02 | ジェネンテック， インコーポレイテッド | モスネツズマブおよびポラツズマブベドチンを用いたｃｄ２０陽性増殖性障害の処置のための方法 |
| CN113637087A (zh) * | 2021-07-09 | 2021-11-12 | 上海易慕峰生物科技有限公司 | 一种提高细胞免疫疗法安全性的嵌合受体和细胞 |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2024206166A1 (en) * | 2023-03-31 | 2024-10-03 | Memorial Sloan-Kettering Cancer Center | Microenvironment actuated t-cells and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2689848A (en) | 1951-02-06 | 1954-09-21 | Wander Ag Dr A | Salts of sulfuric acid esters of xylan |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| ZA936128B (en) | 1992-08-21 | 1995-02-20 | Genentech Inc | Method for treating a LFA-1 mediated disorder |
| JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| PT1976886E (pt) | 2005-12-16 | 2015-03-09 | Amgen Res Munich Gmbh | Meios e processos para o tratamento de doenças tumorais |
| DK2016102T3 (da) | 2006-05-03 | 2012-07-02 | Us Gov Health & Human Serv | Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse |
| AU2007260687B2 (en) * | 2006-06-14 | 2013-12-12 | Provention Bio, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| US20100105889A1 (en) | 2007-03-06 | 2010-04-29 | Pandurang Balwant Deshpande | Process for the preparation of pentosan polysulfate or salts thereof |
| CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发（慕尼黑）股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
| CN103694350B (zh) * | 2007-04-03 | 2018-04-24 | 安进研发（慕尼黑）股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
| US20100183615A1 (en) | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
| CA2694987A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Combinations for the treatment of b-cell proliferative disorders |
| AU2008276451A1 (en) * | 2007-07-17 | 2009-01-22 | Zalicus Inc. | Treatments of B-cell proliferative disorders |
| CA2733706A1 (en) | 2007-08-10 | 2009-02-19 | Y's Therapeutics Co., Ltd. | Modulation of immune responses by administration of roxithromycin or its derivative |
| US8026343B2 (en) * | 2008-08-08 | 2011-09-27 | Dinona Inc. | Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof |
| EP4180458A1 (en) * | 2008-10-01 | 2023-05-17 | Amgen Research (Munich) GmbH | Cross-species-specific psma x cd3 bispecific single chain antibody |
| US8840888B2 (en) * | 2009-10-27 | 2014-09-23 | Micromet Ag | Dosage regimen for administering a CD19XCD3 bispecific antibody |
| HUE048639T2 (hu) * | 2010-10-27 | 2020-08-28 | Amgen Res Munich Gmbh | Eljárás DLBCL kezelésére |
| EP3228315B1 (en) * | 2010-11-10 | 2020-11-25 | Amgen Research (Munich) GmbH | Prevention of adverse effects caused by cd3 specific binding domains |
| AU2012207356A1 (en) * | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| CA2832360C (en) * | 2011-04-28 | 2022-05-03 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CN102875685B (zh) | 2012-09-29 | 2013-12-25 | 郑骏年 | 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途 |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| US9486475B2 (en) * | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
-
2014
- 2014-02-06 JO JOP/2014/0028A patent/JO3529B1/ar active
- 2014-02-07 EP EP14707953.7A patent/EP2953630B1/en active Active
- 2014-02-07 MX MX2015009922A patent/MX368842B/es active IP Right Grant
- 2014-02-07 ES ES14707953T patent/ES2811764T3/es active Active
- 2014-02-07 AU AU2014214020A patent/AU2014214020B2/en active Active
- 2014-02-07 EP EP20182831.6A patent/EP3760210A1/en not_active Withdrawn
- 2014-02-07 WO PCT/EP2014/052406 patent/WO2014122251A2/en not_active Ceased
- 2014-02-07 JP JP2015556506A patent/JP6567425B2/ja active Active
- 2014-02-07 UY UY0001035313A patent/UY35313A/es unknown
- 2014-02-07 TW TW107140068A patent/TW201929865A/zh unknown
- 2014-02-07 CA CA2898032A patent/CA2898032C/en active Active
- 2014-02-07 TW TW103104162A patent/TWI704920B/zh active
- 2014-02-07 MX MX2019012421A patent/MX2019012421A/es unknown
- 2014-02-07 AR ARP140100416A patent/AR094740A1/es unknown
- 2014-02-08 US US14/176,091 patent/US9688760B2/en active Active
-
2017
- 2017-05-24 US US15/604,341 patent/US11084876B2/en active Active
-
2019
- 2019-02-07 AU AU2019200841A patent/AU2019200841B2/en active Active
- 2019-05-28 JP JP2019098999A patent/JP6933684B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170327581A1 (en) | 2017-11-16 |
| UY35313A (es) | 2014-08-29 |
| AU2019200841B2 (en) | 2020-08-13 |
| JP6933684B2 (ja) | 2021-09-08 |
| WO2014122251A3 (en) | 2014-10-02 |
| US9688760B2 (en) | 2017-06-27 |
| MX2015009922A (es) | 2015-09-25 |
| AU2019200841A1 (en) | 2019-02-28 |
| ES2811764T3 (es) | 2021-03-15 |
| WO2014122251A2 (en) | 2014-08-14 |
| MX2019012421A (es) | 2022-10-13 |
| AU2014214020A1 (en) | 2015-07-30 |
| US11084876B2 (en) | 2021-08-10 |
| JP2016514090A (ja) | 2016-05-19 |
| EP3760210A1 (en) | 2021-01-06 |
| HK1216996A1 (zh) | 2016-12-16 |
| EP2953630A2 (en) | 2015-12-16 |
| JP2019178142A (ja) | 2019-10-17 |
| JO3529B1 (ar) | 2020-07-05 |
| JP6567425B2 (ja) | 2019-08-28 |
| TW201929865A (zh) | 2019-08-01 |
| MX368842B (es) | 2019-10-18 |
| AU2014214020B2 (en) | 2018-11-15 |
| TW201442714A (zh) | 2014-11-16 |
| TWI704920B (zh) | 2020-09-21 |
| EP2953630B1 (en) | 2020-07-01 |
| AR094740A1 (es) | 2015-08-26 |
| CA2898032A1 (en) | 2014-08-14 |
| US20140227272A1 (en) | 2014-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2898032C (en) | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains | |
| EP2639534A3 (en) | Refrigerator | |
| ATE518041T1 (de) | Elastisches haltesystem für türpaneel | |
| EP2592207A3 (en) | Vehicle Hinge Assembly | |
| MX2010004476A (es) | Sistema de puerta o ventana de marco fijo. | |
| GB201121980D0 (en) | Switch device | |
| MX2015015049A (es) | Disposicion de sellado para un cristal de ventana de vehiculo motorizado. | |
| MX2017011658A (es) | Montaje de puerta intermedia para vehiculo motorizado. | |
| WO2017067539A3 (de) | Dichtungsvorrichtung für eine schiebetür sowie damit versehene schiebetür | |
| WO2012071124A3 (en) | Integrated floating overmolded snap-ring and seal for a plastic fuel housing assembly | |
| MX357857B (es) | Sistema de bolsa de aire sin costuras para pasajero. | |
| MX2019004880A (es) | Marco de vitrina y ensamblaje de puerta para un exhibidor de mercancia. | |
| EP2792829A3 (en) | Vehicle door latch system | |
| MX339062B (es) | Valvula de control de diafragma que tiene una ubicacion de montaje de diafragma universal. | |
| MX2015003259A (es) | Bisagra de puerta para bolsa de aire para un vehiculo de motor. | |
| WO2012062877A3 (en) | A refrigerator comprising a slidable door shelf with a rotating cover | |
| MX2015017240A (es) | Montaje de parasol que incorpora un sistema de detencion magnetico. | |
| MX2015017941A (es) | Construccion de sello con cinta adhesiva. | |
| EP4298352A4 (en) | FASTENING ARRANGEMENT | |
| MX2015016465A (es) | Sistema de camara oculta con gabinete que incorpora un precinto flexible. | |
| WO2019093896A3 (en) | Mobile accomodation as well as a framed window and framework therefor | |
| MX338580B (es) | Montaje de sello energizado de fuelle para una válvula de control rotatoria. | |
| IN2014DE02327A (OSRAM) | ||
| WO2013180778A3 (en) | Seal assembly | |
| MX371043B (es) | Cubierta de riel guía para la puerta de compartimento de eje móvil. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190122 |